A further 616 people have died in the UK within 28 days of testing positive for coronavirus, bringing the toll to 62,033.
However, as of Friday, Covid-19 has been mentioned on 73,125 death certificates.
The number of new infections reported on Tuesday fell to 12,282 – down from a seven-day average high of more than double that number just less than a month ago, Public Health England figures show.
And according to the most recent government statistics, there are 14,807 patients in hospital with coronavirus. Some 1,458 new patients were reported on Thursday, the latest day for which figures are available.
It comes as the first doses of the Pfizer/BioNTech vaccine were administered across the UK after the jab was approved by regulators last week.
Margaret Keenan, 90, was the first person to receive the inoculation, at 6.31am in University Hospital Coventry, marking the start of a phased rollout of the vaccine to older people, NHS staff and care home workers.
Second in line, just 20 miles from the birthplace of England’s greatest dramatist in Stratford-upon-Avon, was William Shakespeare’s 81-year-old namesake.
Fifty hospital hubs will now be distributing the vaccine, with some 800,000 doses expected to be available within the first week, and up to five million doses in total hoped for by New Year.
On Monday, Downing Street suggested the “majority” of the 25 million people covered by the 10 priority categories set out by the Joint Committee on Vaccination and Immunisation (JCVI) will be vaccinated by the end of February.
Meanwhile, AstraZeneca and the University of Oxford have published the long-awaited analysis of their interim trial results, showing their vaccine to be safe and 90 per cent effective when administered in a half dose followed by a full dose, compared with 62 per cent effective using two full doses.
The data published in The Lancet has already been passed on to drug regulators to finalise their rolling vaccine reviews, and the health secretary Matt Hancock said he is hopeful that regulatory approval will be granted in the next few weeks.
But phase three trials are still ongoing and the report’s author Dr Merryn Voysey said that further analysis of the jab was required to “investigate differences in key subgroups such as older adults, various ethnicities, doses [and] timing of booster vaccines”, adding that researchers will also seek to “determine which immune responses equate to protection from infection or disease”.
And Mr Hancock said he hopes there can be a return to normality by spring, but warned tougher measures may be needed during the winter months.
Register for free to continue reading
Registration is a free and easy way to support our truly independent journalism
By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists
Already have an account? sign in
Join our new commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies